Literature DB >> 20933441

Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling.

Taheri Sathaliyawala1, William E O'Gorman, Melanie Greter, Milena Bogunovic, Vjollca Konjufca, Z Esther Hou, Garry P Nolan, Mark J Miller, Miriam Merad, Boris Reizis.   

Abstract

Dendritic cells (DCs) comprise distinct functional subsets including CD8⁻ and CD8(+) classical DCs (cDCs) and interferon-secreting plasmacytoid DCs (pDCs). The cytokine Flt3 ligand (Flt3L) controls the development of DCs and is particularly important for the pDC and CD8(+) cDC and their CD103(+) tissue counterparts. We report that mammalian target of rapamycin (mTOR) inhibitor rapamycin impaired Flt3L-driven DC development in vitro, with the pDCs and CD8(+)-like cDCs most profoundly affected. Conversely, deletion of the phosphoinositide 3-kinase (PI3K)-mTOR negative regulator Pten facilitated Flt3L-driven DC development in culture. DC-specific Pten targeting in vivo caused the expansion of CD8(+) and CD103(+) cDC numbers, which was reversible by rapamycin. The increased CD8(+) cDC numbers caused by Pten deletion correlated with increased susceptibility to the intracellular pathogen Listeria. Thus, PI3K-mTOR signaling downstream of Flt3L controls DC development, and its restriction by Pten ensures optimal DC pool size and subset composition.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20933441      PMCID: PMC2966531          DOI: 10.1016/j.immuni.2010.09.012

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  51 in total

1.  STAT3 is required for Flt3L-dependent dendritic cell differentiation.

Authors:  Yasmina Laouar; Thomas Welte; Xin-Yuan Fu; Richard A Flavell
Journal:  Immunity       Date:  2003-12       Impact factor: 31.745

2.  Inhibition of natural type I IFN-producing and dendritic cell development by a small molecule receptor tyrosine kinase inhibitor with Flt3 affinity.

Authors:  Roxane Tussiwand; Nobuyuki Onai; Luca Mazzucchelli; Markus G Manz
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

3.  Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures.

Authors:  Shalin H Naik; Anna I Proietto; Nicholas S Wilson; Aleksandar Dakic; Petra Schnorrer; Martina Fuchsberger; Mireille H Lahoud; Meredith O'Keeffe; Qi-xiang Shao; Wei-feng Chen; José A Villadangos; Ken Shortman; Li Wu
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

4.  Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.

Authors:  M Golam Mohi; Christina Boulton; Ting-Lei Gu; David W Sternberg; Donna Neuberg; James D Griffin; D Gary Gilliland; Benjamin G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

5.  Increased dendritic cell numbers impair protective immunity to intracellular bacteria despite augmenting antigen-specific CD8+ T lymphocyte responses.

Authors:  Robert C Alaniz; Sharsti Sandall; Elaine K Thomas; Christopher B Wilson
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

6.  Treatment of neonatal mice with Flt3 ligand leads to changes in dendritic cell subpopulations associated with enhanced IL-12 and IFN-alpha production.

Authors:  Sabine Vollstedt; Meredith O'Keeffe; Bernhard Odermatt; Ryf Beat; Bettina Glanzmann; Matthias Riesen; Ken Shortman; Mark Suter
Journal:  Eur J Immunol       Date:  2004-07       Impact factor: 5.532

7.  Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.

Authors:  E Maraskovsky; K Brasel; M Teepe; E R Roux; S D Lyman; K Shortman; H J McKenna
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

8.  Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo.

Authors:  Holger Karsunky; Miriam Merad; Antonio Cozzio; Irving L Weissman; Markus G Manz
Journal:  J Exp Med       Date:  2003-07-21       Impact factor: 14.307

9.  The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3.

Authors:  Angela D'Amico; Li Wu
Journal:  J Exp Med       Date:  2003-07-21       Impact factor: 14.307

10.  Pten dose dictates cancer progression in the prostate.

Authors:  Lloyd C Trotman; Masaru Niki; Zohar A Dotan; Jason A Koutcher; Antonio Di Cristofano; Andrew Xiao; Alan S Khoo; Pradip Roy-Burman; Norman M Greenberg; Terry Van Dyke; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  PLoS Biol       Date:  2003-10-27       Impact factor: 8.029

View more
  80 in total

1.  Rapamycin-induced enhancement of vaccine efficacy in mice.

Authors:  Chinnaswamy Jagannath; Pearl Bakhru
Journal:  Methods Mol Biol       Date:  2012

2.  Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.

Authors:  Moanaro Biswas; Debalina Sarkar; Sandeep R P Kumar; Sushrusha Nayak; Geoffrey L Rogers; David M Markusic; Gongxian Liao; Cox Terhorst; Roland W Herzog
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 3.  A STATus report on DC development.

Authors:  Haiyan S Li; Stephanie S Watowich
Journal:  J Leukoc Biol       Date:  2012-05-01       Impact factor: 4.962

Review 4.  Complexity of dendritic cell subsets and their function in the host immune system.

Authors:  Rahul Kushwah; Jim Hu
Journal:  Immunology       Date:  2011-06-01       Impact factor: 7.397

Review 5.  Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues.

Authors:  D Sichien; B N Lambrecht; M Guilliams; C L Scott
Journal:  Mucosal Immunol       Date:  2017-02-15       Impact factor: 7.313

6.  Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity.

Authors:  Yaron Carmi; Tyler R Prestwood; Matthew H Spitzer; Ian L Linde; Jonathan Chabon; Nathan E Reticker-Flynn; Nupur Bhattacharya; Hong Zhang; Xiangyue Zhang; Pamela A Basto; Bryan M Burt; Michael N Alonso; Edgar G Engleman
Journal:  JCI Insight       Date:  2016-11-03

Review 7.  MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells.

Authors:  Russell G Jones; Edward J Pearce
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

8.  Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells.

Authors:  Yanyan Wang; Gonghua Huang; Hu Zeng; Kai Yang; Richard F Lamb; Hongbo Chi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

Review 9.  Regulatory myeloid cells in transplantation.

Authors:  Brian R Rosborough; Dàlia Raïch-Regué; Heth R Turnquist; Angus W Thomson
Journal:  Transplantation       Date:  2014-02-27       Impact factor: 4.939

10.  Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesis.

Authors:  Fukun Guo; Shuangmin Zhang; Matthew Grogg; Jose A Cancelas; Melinda E Varney; Daniel T Starczynowski; Wei Du; Jun-Qi Yang; Wei Liu; George Thomas; Sara Kozma; Qishen Pang; Yi Zheng
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.